Compare RGLD & STE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGLD | STE |
|---|---|---|
| Founded | 1981 | 1985 |
| Country | United States | United States |
| Employees | N/A | 3700 |
| Industry | Precious Metals | Industrial Specialties |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.2B | 21.7B |
| IPO Year | 1995 | 2018 |
| Metric | RGLD | STE |
|---|---|---|
| Price | $232.72 | $223.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $231.14 | ★ $275.20 |
| AVG Volume (30 Days) | ★ 934.6K | 826.4K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | 0.84% | ★ 1.14% |
| EPS Growth | 32.74 | ★ 62.73 |
| EPS | ★ 6.69 | 5.69 |
| Revenue | $1,030,471,000.00 | ★ $5,459,515,000.00 |
| Revenue This Year | $94.45 | $9.88 |
| Revenue Next Year | $3.32 | $6.32 |
| P/E Ratio | ★ $33.79 | $39.07 |
| Revenue Growth | ★ 43.24 | 6.24 |
| 52 Week Low | $150.75 | $204.90 |
| 52 Week High | $306.25 | $269.44 |
| Indicator | RGLD | STE |
|---|---|---|
| Relative Strength Index (RSI) | 37.39 | 40.96 |
| Support Level | $216.53 | $223.10 |
| Resistance Level | $235.52 | $231.27 |
| Average True Range (ATR) | 9.87 | 5.80 |
| MACD | -5.17 | 0.73 |
| Stochastic Oscillator | 25.10 | 52.81 |
Royal Gold Inc enquires and manages precious metal royalties and streams with a focus on gold. The company purchases a percentage of the metal produced from a mineral property for an initial payment without assuming responsibility for mining operations. Similarly, precious metal streams are purchase agreements with mine operators providing the right to purchase all or a portion of one or more metals produced from a mine in exchange for an upfront deposit payment. Generally, Royal Gold does not work on the properties in which it holds royalty and streaming assets. The company owns a portfolio of producing, development, evaluation, and exploration royalties and streams, and the majority of group revenue is generated from Canada, Mexico, Chile, and the United States.
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.